evonetix Stock

evonetix is seeking to develop and commercialise a new approach to the synthesis of DNA.

Sign up today and learn more about evonetix Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About evonetix Stock

We are a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

Funding History

January 2018$12.3M
July 2018$1.3M

Management

Chief Technology Officer

Matthew Hayes

Director

Ray Edgson

Chief Scientific Officer

Joseph Brennan

CEO

Tim Brears

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo